Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.36 |
| ▸ | CDK2 | P24941 | 9/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239220 | 1.00 | OPRL1 (0.36) | OPRL1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL10239077 | 1.00 | OPRL1 (0.36) | OPRL1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7883870 | 1.00 | OPRL1 (0.36) | OPRL1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL10234998 | 0.93 | CHEK1 (0.36) | CHEK1CCNA2CDK2CCNA1OPRK1 | |
| SCHEMBL10235083 | 0.93 | CHEK1 (0.36) | CHEK1CCNA2CDK2CCNA1OPRK1 | |
| SCHEMBL10235085 | 0.93 | CHEK1 (0.36) | CHEK1CCNA2CDK2CCNA1OPRK1 | |
| SCHEMBL10235025 | 0.91 | CHEK1 (0.37) | CHEK1CCNA2CDK2CCNA1MET | |
| SCHEMBL10235021 | 0.91 | CHEK1 (0.37) | CHEK1CCNA2CDK2CCNA1MET | |
| SCHEMBL10239296 | 0.87 | MET (0.38) | CHEK1CCNA2CDK2CCNA1MET | |
| SCHEMBL10239304 | 0.87 | MET (0.38) | CHEK1CCNA2CDK2CCNA1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | OPRL1 4510/4885CHEK1 461/4885CCNA2 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.